今天3分钟我们来聊聊AI制药突破血脑屏障，帕金森治疗新曙光

英矽智能与衡泰生物合作开发的AI设计口服NLRP3抑制剂ISM8969获中国临床试验批准，用于帕金森病治疗。该药可穿透血脑屏障，从源头阻断神经炎症链条，有望改变现有仅能改善症状的治疗局面。目前全球在研NLRP3抑制剂多因无法透脑受限，此药为神经退行性疾病治疗带来新方向本期参考文献：英矽智能港交所公告/美通社新闻稿：ISM8969/HT-001获NMPA临床批件，2026-08-03第一财经. 英矽智能NLRP3抑制剂获NMPA临床批件. https://www.yicai.com/news/103302151.html制药网. 英矽智能×衡泰生物NLRP3抑制剂获NMPA临床批件. https://m.zyzhan.com/news/detail/99924.html华盛通/复健资本鹏复基金报道. https://www.hstong.com/news/detail/26080318150389765雪球. 英矽智能ISM8969详细解读. https://xueqiu.com/3153096877/403228560前往小宇宙评论区与主播互动

Episode metadata supplied by the publisher feed · Published Aug 11, 2026

Embed this episode

Attribution link and audio player

Ready to play

今天3分钟我们来聊聊AI制药突破血脑屏障，帕金森治疗新曙光

0:00 6:58

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

峰人学院

Frequently Asked Questions

How long is this episode of 源于细胞BioInsid的个人播客?

This episode is 6 minutes long.

When was this 源于细胞BioInsid的个人播客 episode published?

This episode was published on August 11, 2026.

Can I download this 源于细胞BioInsid的个人播客 episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!